ARG23874
Goat anti-Human IgG (Fc) antibody (HRP), pre-adsorbed
Goat anti-Human IgG (Fc) antibody (HRP), pre-adsorbed for ELISA,FLISA,Flow cytometry,Western blot and Human
Publication5
Overview
| Product Description | HRP-conjugated Goat Polyclonal antibody recognizes Human IgG (Fc) |
|---|---|
| Tested Reactivity | Hu |
| Species Does Not React With | Ms, Rat, Bov, Chk, Goat, Gpig, Hm, Hrs, Rb, Sheep |
| Tested Application | ELISA, FACS, FLISA, WB |
| Specificity | Reacts with the Fc region of human IgG. Minimal reaction to Fab region of human IgG and other human immunoglobulins. Minimal cross reactivity with bovine, mouse, horse, rat, goat, sheep, rabbit, hamster, chicken, and guinea pig serum proteins. |
| Host | Goat |
| Clonality | Polyclonal |
| Isotype | IgG |
| Target Name | IgG (Fc) |
| Antigen Species | Human |
| Immunogen | Human IgG |
| Conjugation | HRP |
Application Instructions
| Pre Adsorbed | Human IgG Fab, IgM, and IgA; Rabbit, mouse, rat, bovine, horse, hamster, goat, sheep, chicken, and guinea pig serum proteins. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Application Suggestion |
|
||||||||||
| Application Note | * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. |
Properties
| Form | Liquid |
|---|---|
| Purification | Affinity purification with immunogen. |
| Buffer | PBS (pH 7.4) and 50% Glycerol. |
| Stabilizer | 50% Glycerol |
| Storage Instruction | Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Specific References
Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19
ELISA /
Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity
ELISA /
Persistent Antibody Responses up to 18 Months after Mild SARS-CoV-2 Infection
ELISA /
Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer
ELISA /
Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection
ELISA /
